Research suggests that the medication, a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, originally developed to manage type 2 diabetes, may be able to treat a wide range of conditions involving impulse control, like binge eating disorder
This is different from medications focused only on appetite and may contribute to the higher weight-loss percentages seen in trials
Microdosing GLP-1s has benefits beyond weight loss
Anything that independently reduces blood glucose berberine, chromium, bitter melon, high-dose cinnamon creates an additive hypoglycemia risk when combined with a GLP-1 drug
Nausea, vomiting, diarrhoea, and constipation are the most common the same profile as other GLP-1 medications